Journal Article
. 2016 Jun; 22(20):5043-5048.
doi: 10.1158/1078-0432.CCR-16-0155.

Cross-Stratification and Differential Risk by Breast Cancer Index and Recurrence Score in Women with Hormone Receptor-Positive Lymph Node-Negative Early-Stage Breast Cancer

Ivana Sestak 1 Yi Zhang 2 Brock E Schroeder 2 Catherine A Schnabel 2 Mitch Dowsett 3 Jack Cuzick 4 Dennis Sgroi 5 
  • PMID: 27252417
  •     5 citations


Purpose: Previous results from the TransATAC study demonstrated that both the Breast Cancer Index (BCI) and the OncotypeDX Recurrence Score (RS) added significant prognostic information to clinicopathologic factors over a 10-year period. Here, we examined cross-stratification between BCI and RS to directly compare their prognostic accuracy at the individual patient level.

Experimental Design: A total of 665 patients with hormone receptor-positive (HR+) and lymph node-negative disease were included in this retrospective analysis. BCI and RS risk groups were determined using predefined clinical cut-off points. Kaplan-Meier estimates of 10-year risk of distant recurrence (DR) and log-rank tests were used to examine cross-stratification between BCI and RS.

Results: As previously reported, both RS and BCI were significantly prognostic in years 0 to 10. BCI provided significant additional prognostic information to the Clinical Treatment Score (CTS) plus RS (ΔLR-χ2 = 11.09; P < 0.001), whereas no additional prognostic information was provided by RS to CTS plus BCI (ΔLR-χ2 = 2.22; P = 0.1). Restratification by BCI of the low and intermediate RS risk groups led to subgroups with significantly different DR rates (P < 0.001 and P = 0.003, respectively). In contrast, restratified subgroups created by RS of BCI risk groups did not differ significantly.

Conclusions: In this retrospective analysis, BCI demonstrated increased prognostic accuracy versus RS. Notably, BCI identified subsets of RS low and RS intermediate risk patients with significant and clinically relevant rates of DR. These results indicate that additional subsets of women with HR+, lymph node-negative breast cancer identified by BCI may be suitable candidates for adjuvant chemotherapy or extended endocrine therapy. Clin Cancer Res; 22(20); 5043-8. ©2016 AACRSee related commentary by Brufsky and Davidson, p. 4963.

Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Adam M Brufsky, Nancy E Davidson.
Clin Cancer Res, 2016 Aug 16; 22(20). PMID: 27521446    Free PMC article.
Prognostic immune-related gene models for breast cancer: a pooled analysis.
Jianli Zhao, Ying Wang, +6 authors, Kai Chen.
Onco Targets Ther, 2017 Oct 06; 10. PMID: 28979134    Free PMC article.
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Hege O Ohnstad, Elin Borgen, +11 authors, Bjørn Naume.
Breast Cancer Res, 2017 Nov 16; 19(1). PMID: 29137653    Free PMC article.
Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
Maria B Padua, Poornima Bhat-Nakshatri, +12 authors, Harikrishna Nakshatri.
Breast Cancer Res, 2018 May 04; 20(1). PMID: 29720215    Free PMC article.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2020 Mar 27; 8(1). PMID: 32210163    Free PMC article.